Anavex Life Sciences Corp AVXL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Law Offices of Frank R. Cruz Encourages Anavex Life Sciences Corp. (AVXL) Shareholders To Inquire About Securities Fraud Class Action
-
Securities Fraud Investigation Into Anavex Life Sciences Corp. (AVXL) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines - AVXL
-
Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
-
AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit with SBS Law
-
Securities Class Action Filed Against Anavex Life Sciences Corp. – AVXL Investors Encouraged to Contact Kirby McInerney LLP
-
Securities Fraud Investigation Into Anavex Life Sciences Corp. (AVXL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
-
AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit Filed by The Rosen Law Firm
Trading Information
- Previous Close Price
- $2.02
- Day Range
- $1.88–2.01
- 52-Week Range
- $1.88–10.38
- Bid/Ask
- $1.88 / $1.90
- Shares Outstanding
- 92.70M
- Market Cap
- $175.20M
- Volume/Avg
- 1,338 / 922,016
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 34
- Website
- https://www.anavex.com
Valuation
|
Metric
|
AVXL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.56 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AVXL
|
|---|---|
Quick Ratio | 15.51 |
Current Ratio | 15.62 |
Interest Coverage | — |
Quick Ratio
AVXL
Profitability
|
Metric
|
AVXL
|
|---|---|
Return on Assets (Normalized) | −21.22% |
Return on Equity (Normalized) | −22.84% |
Return on Invested Capital (Normalized) | −26.69% |
Return on Assets
AVXL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|yllB$ws | LOCK|p^kTY | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|F?%!<! | LOCK|?@&?Q | $76B | |||
| Moderna Inc
MRNA
| LOCK|^LJy?R$ | LOCK|JQn | $75B | |||
| argenx SE ADR
ARGX
| LOCK|vPMZ$^ | LOCK|k&# | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|klLkGT | LOCK|@P$ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|C?!R#k> | LOCK|kzPK | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>?##>^#C | LOCK|DPm^ | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|b&h><rm | LOCK|N> | $24B | |||
| Incyte Corp
INCY
| LOCK|D@C&QB> | LOCK|K> | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^!GzP$x | LOCK|g? | $15B |
United States